Contact
Please use this form to send email to PR contact of this press release:
FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations
TO:
Please use this form to send email to PR contact of this press release:
FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations
TO: